Rivermark News

‍Milwaukee, WI – [Date], 2025– Rivermark Medical, a urology-focused medical device company committed toredefining benign prostatic hyperplasia (BPH) treatment through simple,innovative solutions, today announced the enrollment of the first patient inits RAPID III clinical study. RAPID III is a prospective, multicenter,randomized pivotal clinical trial (NCT06849258) designed to evaluate the safetyand effectiveness of the FloStent™ System in men experiencing lower urinarytract symptoms caused by BPH.

The first procedure wassuccessfully completed at Freedman Urology in Las Vegas, Nevada, by SheldonFreedman, M.D., a board-certified urologist and early adopter of innovative BPHtherapies. “The FloStent represents a meaningful step forward in providing menwith a non-surgical, reversible treatment option for BPH,” said Dr. Freedman.“We’re excited to be the first site to enroll in the RAPID III study and lookforward to offering our patients an option that preserves confidence while effectivelyaddressing urinary symptoms.”

FloStent is a first-line devicetreatment for BPH, delivered in an outpatient setting during a routinecystoscopy using any type of flexible cystoscope. The FloStent is designed torestore normal urinary flow, minimize patient recovery time, and preservefuture treatment options—enabling a continuum of care for both patients andproviders. Unlike other therapies, the device has no capital component, and canbe easily retrieved or adjusted after implantation using standard urologicaltools.

Led and co-founded by practicingurologist and CEO Adam Kadlec, MD, Rivermark Medical’s solutions are groundedin real-world clinical needs. “FloStent is designed to offer rapid symptomrelief without damaging tissue, thus reducing the risks associated with surgeryand other irreversible treatment options, which makes it a logical first-stepoption for the millions of men seeking treatment for BPH.” said Dr. Kadlec. “Enrollingthe first patient in the RAPID III study marks a major milestone for Rivermarkand reflects the growing demand for simple, effective, and accessible BPHtherapies,”

BPH affects nearly 40 million menin the U.S. and over 500 million men globally. While not life-threatening, itsignificantly impacts quality of life. Current treatment options often requiretrade-offs between efficacy, invasiveness, and side effects. By enablingproviders to deliver a zero-capital BPH treatment in the outpatient setting,Rivermark empowers a broad range of clinicians to deliver high-qualityoutcomes.

For more information about the RAPID III trial, visit clinicaltrials.gov.

About Rivermark Medical
Rivermark Medical is redefining BPH treatment with simple, innovative therapiesthat prioritize patient outcomes and provider ease.

For more information, visit rivermarkmedical.com.

CAUTION: Investigational Device.
The FloStent™ is limited by Federal (or United States) law toinvestigational use.

Media Contact:
Greg Borecki
Vice President, Market Development
Greg@rivermarkmedical.com

‍